IDDM in an adolescent patient with common variable immunodeficiency.
Metin
A
A
Tezcan
I
I
Ozyürek
H
H
D000293:Adolescent; D016516:CD4-CD8 Ratio; D002648:Child; D017074:Common Variable Immunodeficiency / Q000150:complications* / Q000276:immunology / Q000628:therapy; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000276:immunology; D015234:HLA-A Antigens / Q000032:analysis; D059871:HLA-A24 Antigen; D015235:HLA-B Antigens / Q000032:analysis; D059909:HLA-B14 Antigen; D015795:HLA-B8 Antigen / Q000032:analysis; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008213:Lymphocyte Activation; D008297:Male
D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D015235:HLA-B Antigens; D059909:HLA-B14 Antigen; D015795:HLA-B8 Antigen; D016756:Immunoglobulins, Intravenous